Buy INNO-EXFO Glyco Age (2403) Online
Original price was: $65.00.$55.00Current price is: $55.00.
INNO-EXFO Glyco Age (2403)
Minimum Order : 2 Pieces
Related products
-
Buy Pluryal Mesoline Bodyfirm Online
Original price was: $85.00.$75.00Current price is: $75.00.Add to cartPluryal Mesoline Bodyfirm
Mesoline BODYFIRM makes your skin firmer by reducing cellulite and stimulating natural lymphatic drainage. For Sale Pluryal Mesoline Bodyfirm We recommend having 4 to 5 weekly sessions and a “top-up” treatment every 2 – 3 months, depending on your individual needs.
-
Buy Pluryal Mesoline Antiox Online
Original price was: $80.00.$65.00Current price is: $65.00.Add to cartPluryal Mesoline Antiox
Pluryal® Mesoline is a range of science-based anti-aging products for aesthetic mesotherapy treatments. Specially selected ingredients target specific problems of the face, hair and body. They can be used in microneedling or injection treatments.
-
BCN Eye Relief Patches 8094 4×2 hydrogel patches
Original price was: $18.00.$12.00Current price is: $12.00.Add to cartBCN Eye Relief Patches 8094 4×2 hydrogel patches For Sale
Minimum order : 10 pieces
BCN Eye Relief Patches are specifically formulated with an active ingredient combination that helps improve the appearance of dark circles and puffiness under the eyes, providing comfort and radiance to the eye contour.
-
Buy Manificare Derma Booster 50
Original price was: $70.00.$59.00Current price is: $59.00.Add to cartManificare Derma Booster 50
Manificare® is a range of cosmeceutic treatments dedicated to specific skin problems.
Derma Booster 50 is biorevitalizing cocktail of 50 active ingredients to smooth out fine lines and deeply moisturize the skin. -
Buy Pluryal Mesoline Clear Online
Original price was: $80.00.$69.00Current price is: $69.00.Add to cartPluryal Mesoline Clear
Pluryal Mesoline is a range of science-based anti-aging products for aesthetic mesotherapy treatments. Specially selected ingredients target specific problems of the face, hair and body.
Reviews
There are no reviews yet.